Financials data is unavailable for this security.
View more
Year on year Glenmark Life Sciences Ltd had no change in net income (4.71bn) despite revenues that grew 5.64% from 21.61bn to 22.83bn. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 22.15% to 25.23%.
| Gross margin | 54.92% |
|---|---|
| Net profit margin | 19.21% |
| Operating margin | 24.97% |
| Return on assets | 14.03% |
|---|---|
| Return on equity | 17.18% |
| Return on investment | 16.69% |
More ▼
Cash flow in INRView more
In 2024, Glenmark Life Sciences Ltd increased its cash reserves by 6.20%, or 175.91m. The company earned 4.14bn from its operations for a Cash Flow Margin of 18.11%. In addition the company used 1.16bn on investing activities and also paid 2.79bn in financing cash flows.
| Cash flow per share | 39.12 |
|---|---|
| Price/Cash flow per share | 27.53 |
| Book value per share | 207.17 |
|---|---|
| Tangible book value per share | 205.76 |
More ▼
Balance sheet in INRView more
| Current ratio | 4.52 |
|---|---|
| Quick ratio | 3.03 |
| Total debt/total equity | 0.0063 |
|---|---|
| Total debt/total capital | 0.0063 |
More ▼
Growth rates in INR
Year on year, growth in dividends per share increased 7.14% while earnings per share excluding extraordinary items growth only marginally increased 0.71%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 65.10% |
| EPS growth(5 years) | 19.18 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -16.47 |
More ▼
